Melbourne, Doherty Institute, 2026.
Adelaide, Aboriginal Health Council of SA, 2026.
Developed to facilitate a standardised evidence-based approach to control programs at the comprehensive primary health care level.
Geneva, World Health Organization, 2026.
This document consolidates, for the first time, WHO recommendations on the prevention, testing, treatment and monitoring of hepatitis B and C, and includes testing strategies for hepatitis D. Drawing on a decade of evidence-based guidance issued between 2015 and 2025, it provides a single, practical handbook to support global progress toward eliminating viral hepatitis by 2030.
New York, Medical Professionals Reference, 2026.
Review showed that since the implementation of the universal birth dose of the hepatitis B vaccine in 1991, the incidence of pediatric hepatitis B had declined by approximately 99% in the USA. The data further indicated that delaying the first dose was not linked to any improvements in safety or vaccine efficacy.
London, Elsevier, 2025.
Understanding patient preferences for hepatitis C virus (HCV) testing is essential to improve uptake and support elimination efforts. Despite innovative testing modalities, limited research examines how preferences influence testing choices. This study compared the uptake of HCV testing modalities when participants were given a choice. Findings highlight the importance of offering rapid, staff-assisted HCV testing to improve uptake among at-risk populations.
Oxford, Oxford University Press, 2025.
A decentralized, nurse-led, statewide model of care was highly effective in treating large numbers of people in prison with hepatitis C and achieved high rates of SVR12. Nurse-led prison programs are playing a crucial role in eliminating hepatitis C as a public health threat in Australia.
Sydney, Hepatitis NSW, 2026.
If you have hep B, this page covers the types of appointments you might have, things to bring to your appointment, and some costs and rebates.
Sydney, Hepatitis NSW, 2026.
If you have hep C, this page covers the types of appointments you might have, things to bring to your appointment, and some costs and rebates.
London, Elsevier, 2025.
The high HCV reinfection incidence in prisons emphasises the need to enhance prison-based harm reduction measures including access to sterile injecting equipment, currently prohibited in Australian prisons.
London, Springer Nature, 2025.
By understanding what Vietnamese people know about hepatitis B and how they access health information, these findings can be used to inform health promotion campaigns using print, media, and radio to ensure wide reach.
Sydney, Kirby Institute, 2025.
The National Prisons Hepatitis Network (NPHN) Surveillance Dashboard has been created to provide crucial insights to help address hepatitis C in Australian prisons.
Brisbane, Hepatitis Queensland and Cancer Council Queensland, 2026.
Viral hepatitis remains a central driver of liver cancer risk in Queensland. Makes recommendations for priority action.
Canberra, Hepatitis Australia, 2026.
Examines the consequences of failing to meet agreed targets.
Geneva, World Hepatitis Alliance, 2026.
Viral hepatitis is a leading cause of death globally, despite being preventable, treatable, and, in the case of hepatitis C, curable. Notwithstanding significant progress, the global response to hepatitis now fails to match the scale of the crisis, shockingly, hepatitis B deaths continue to increase in all regions. This declaration calls for the resources to implement existing tools and strategies to prevent deaths from viral hepatitis.
For enquiries or feedback, please contact the librarian at Librarian@hepatitissa.asn.au.
| Address: | 3 Hackney Road Hackney SA 5069 |
| Phone: | (08) 8362 8443 |
| Fax: | (08) 8362 8559 |
| Email: | Librarian@hepatitissa.asn.au |
| Post: | PO Box 782 Kent Town SA 5071 |
Monday – Friday
9am to 5pm
Hepatitis SA is a non-profit, community-based organisation that provides information, education and support services to South Australians affected by hepatitis B and hepatitis C.